by Alicia Gailliez, Business Development Manager, One Nucleus
Funding supports expansion of manufacturing and commercial capacity for SemaCyte microcarrier platform
Join Us for the Connect@Babraham Conferencing & Events Open Day
Connect@Babraham is a specialist conferences and events venue at the heart of a world-class science campus.
Whether you’re planning your next meeting, conference or event, this is your chance to explore a venue designed to inspire, connect and elevate every occasion.
What to Expect
This open day marks the first time we’ve opened our doors to showcase the full potential of our facilities to the wider business community. During your visit, you will:
At Cancer Research UK, we exist to beat cancer.
We are looking for 2 Senior Data Scientists to join our Marketing Fundraising and Engagement (MFE) directorate, enabling data driven decisions that drive impact.
At Cancer Research UK, we exist to beat cancer.
Cancer Research Horizons are seeking an experienced Scientist to provide lab‑based scientific leadership and intellectual input across the design, development, execution, and analysis of biochemical experiments. You will characterise target mechanisms, drive hit‑identification campaigns, generate high‑quality SAR/SKR data, and deliver compound mechanism‑of‑action studies. Your contributions will be central to shaping project strategy and advancing portfolio objectives.
Singleron Biotechnologies is an innovative life sciences tools company dedicated to applying groundbreaking single cell analysis techniques to research, clinical diagnosis, drug development, and health management. The company was incorporated in 2018 and currently has offices and laboratories in Germany, US, Singapore, and China.
Singleron is seeking motivated and ambitious talent in the field of single cell analysis and next generation sequencing as
Technical Sales Specialist– Single Cell Sequencing, UK
In this episode, host Sonjoy Brahma, VP of Clinical Operations at tranScrip, is joined by Joab Williamson of Faron Pharmaceuticals to explore the operational realities of working within small emerging biotech companies. They discuss the challenges of rare oncology development, how cash runway and clinical milestones shape strategy, and why flexibility, external expertise and careful planning are essential to balanced decision-making.
Peptide therapeutics offer highly specific and versatile treatments for complex and previously undruggable targets. High-throughput peptide library screening has accelerated discovery. However, traditional platforms such as phage or mRNA display are inherently limited by biological translation processes. DNA-encoded library (DEL) technology provides an alternative, enabling incorporation of unnatural amino acids and diverse cyclization strategies, and producing peptides with improved stability and prolonged retention.
Sandwich, UK — 25 March 2026: Discovery Park, Kent’s science and innovation hub, has launched the sixth edition of its Discovery Spark accelerator programme, welcoming 11 startups to its campus in Sandwich.